(redirected from Soft tissue sarcoma)
Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms, Wikipedia.


(särkō`mə), highly malignant tumor arising in connective- and muscle-cell tissue. It is the result of oncogenes (the cancer causing genes of some viruses) and proto-oncogenes (cancer causing genes in human cells). It may affect bone, cartilage, blood vessels, lymph nodes, and skin. See cancercancer,
in medicine, common term for neoplasms, or tumors, that are malignant. Like benign tumors, malignant tumors do not respond to body mechanisms that limit cell growth.
..... Click the link for more information.
; neoplasmneoplasm
or tumor,
tissue composed of cells that grow in an abnormal way. Normal tissue is growth-limited, i.e., cell reproduction is equal to cell death. Feedback controls limit cell division after a certain number of cells have developed, allowing for tissue repair
..... Click the link for more information.



a malignant tumor that consists of connective tissue. Mesenchymomas, which are sarcomas made up of embryonic connective tissue (mesenchyma), are distinguished from sarcomas made up of mature tissues of mesenchymal origin, for example, bone sarcomas (osteosarcomas), cartilaginous sarcomas (chondrosarcomas), vascular sarcomas (angiosarcomas), hematopoietic sarcomas (reticulosarcomas), muscular sarcomas (leiomyosarcomas, rhabdosarcomas), and sarcomas of skeletal nerve tissue (gliosarcomas).

Sarcomas constitute about 10 percent of all malignant tumors; they occur relatively more often in some African and Asian countries. The most common sarcomas are bone tumors and tumors of soft tissues, including muscular, vascular, and nerve tissues. Sarcomas of the hematopoietic organs occur less frequently. Histomorphologically, there are round-cell, polymorphocellular (sometimes giant-cell), and spindle-cell sarcomas, all of which differ in the shape and size of the cells, and fibrosarcomas, in which fibrous elements predominate over cellular elements.

All malignant tumors are characterized by growing into and destroying surrounding tissues; this property is especially pronounced in sarcomas. The early stages of cancers differ from the early stages of sarcomas; cancers metastasize to the nearest lymph nodes, while sarcomas usually spread by way of the bloodstream and frequently metastasize to remote organs.

The principles and methods of diagnosis, preventive measures, and treatment of sarcomas are the same as those used for other malignant tumors.


Klinicheskaia onkologiia. Edited by N. N. Blokhin and B. E. Peterson, vols. 1–2. Moscow, 1971.



A malignant tumor arising in connective tissue and composed principally of anaplastic cells that resemble those of supportive tissues.


Pathol a usually malignant tumour arising from connective tissue
References in periodicals archive ?
Histologic grading is an important prognostic factor and indicator of metastatic risk in adult soft tissue sarcomas.
Current pathology work-up of extremity soft tissue sarcomas, evaluation of the validity of different techniques.
According to the literature only 11-12% of the retroperitoneal soft tissue sarcomas have metastases at the time of diagnosis (Strauss and Hayes, 2010; Pisters, 2009).
Regarding soft tissue sarcoma, Halaven was approved in the United States for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen in January 2016, and was approved in Japan for the treatment of soft tissue sarcoma in February 2016.
Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection.
Malignant vascular tumors in children and adolescents: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group.
Leiomyosarcoma is the third most common soft tissue sarcoma.
In the second half of 2013, CytRx expects to announce clinical data from an international Phase 2b clinical trial with aldoxorubicin as a first-line therapy in patients with advanced soft tissue sarcoma who are ineligible for surgery.
announced today that the results of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven(R) (eribulin mesylate) in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma)[1] have been published in the online version of The Lancet, a leading medical journal that is highly regarded worldwide.
M2 EQUITYBITES-December 2, 2015-CytRx completes target enrollment of 400 soft tissue sarcoma patients under pivotal global Phase 3 clinical trial of aldoxorubicin
A snapshot of the global therapeutic scenario for Soft Tissue Sarcoma.
Sixty-seven samples were obtained from patients with soft tissue sarcoma.